Category: Press Releases

FDA Approves Medicines360’s Supplemental New Drug Application for LILETTA^® (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding

Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer 

Medicines360 Applauds U.S. Congress for Enshrining Nonprofit Pharma in Federal Law for the First Time

FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Medicines360 Calls on U.S. Congress to Pass Affordability is Access Act Without Delay 

In the Wake of Supreme Court Decision, Medicines360 Stands With Women